

CITATION REPORT

List of articles citing

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

DOI: 10.2217/fon.11.2

Future Oncology, 2011, 7, 263-83.

Source: <https://exaly.com/paper-pdf/49967159/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
205	Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. 2011 , 3, 451-70		26
204	The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30). <i>Future Oncology</i> , 2012 , 8, 13-5	3.6	2
203	MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. 2012 , 11, 1593-602		39
202	Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets. 2012 , 5, 963-90		12
201	Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. 2012 , 14, 855-67		26
200	The spreading influence of platelet HDACs. 2012 , 120, 4118-9		
199	The bromodomain interaction module. 2012 , 586, 2692-704		267
198	Development and therapeutic impact of HDAC6-selective inhibitors. 2012 , 84, 756-65		107
197	Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. 2012 , 106, 77-84		120
196	Histone deacetylase inhibitors and rational combination therapies. 2012 , 116, 199-237		35
195	Histone deacetylase inhibitors in the generation of the anti-tumour immune response. 2012 , 90, 33-8		22
194	The role of bromodomain proteins in regulating gene expression. 2012 , 3, 320-43		78
193	DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer. 2012 ,		
192	Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy. 2012 , 18, 2436-42		31
191	Multiple roles of class I HDACs in proliferation, differentiation, and development. 2012 , 69, 2173-87		129
190	Sensitization of tumor cells by targeting histone deacetylases. 2012 , 83, 987-94		26
189	Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity. 2013 , 8, 9		10

188	The epigenome as a potential mediator of cancer and disease prevention in prenatal development. 2013 , 71, 441-57	15
187	Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases. 2013 , 4, 858-62	18
186	Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. 2013 , 13, 215	151
185	Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience. 2013 , 108, 3-16	13
184	Epigenetic alterations in oncogenesis. Preface. 2013 , 754, v-vii	7
183	Chromatin remodeling--a novel strategy to control excessive alcohol drinking. 2013 , 3, e231	114
182	Epigenetic targeting therapies to overcome chemotherapy resistance. 2013 , 754, 285-311	18
181	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. 2013 , 56, 427-36	116
180	Targeting class I histone deacetylases in cancer therapy. 2013 , 17, 29-41	53
179	Long-range transcriptional regulation of breast cancer genes. 2013 , 52, 113-25	5
178	The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. 2013 , 109, 126-32	19
177	Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. 2013 , 10, 337-52	57
176	Histone deacetylase regulation of ATM-mediated DNA damage signaling. 2013 , 12, 2078-87	76
175	Chromatin remodeling: a new landscape to treat harmful alcohol-use disorders. 2013 , 5, 2011-3	1
174	New targeted therapies and other advances in the management of anaplastic thyroid cancer. 2013 , 25, 44-9	16
173	Histone deacetylase inhibitors suppress immune activation in primary mouse microglia. 2013 , 91, 1133-42	62
172	The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. 2013 , 4, e810	59
171	Chromatin acetylation at transcription start sites and vitamin D receptor binding regions relates to effects of 1,25-dihydroxyvitamin D3 and histone deacetylase inhibitors on gene expression. 2013 , 41, 110-24	66

170	Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity. 2014 , 6, 116-27	26
169	Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment. 2014 , 23, 291-4	16
168	Histone deacetylase inhibitors in cancer therapy. A review. 2014 , 158, 161-9	46
167	Taxanes: impact on breast cancer therapy. 2014 , 25, 512-21	21
166	Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. 2014 , 347, 183-90	38
165	Targeting bromodomains: epigenetic readers of lysine acetylation. 2014 , 13, 337-56	880
164	Epigenetics and oncology. 2014 , 34, 495-505	41
163	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. 2014 , 86, 639-52	35
162	Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects. 2014 , 74, 7475-86	10
161	Molecular mechanisms of endometrial stromal sarcoma and undifferentiated endometrial sarcoma as premises for new therapeutic strategies. 2014 , 354, 21-7	11
160	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. 2014 , 13, 673-91	1028
159	Targeting homologous recombination-mediated DNA repair in cancer. 2014 , 18, 427-58	39
158	Mining the epigenetic landscape of tissue polarity in search of new targets for cancer therapy. 2015 , 7, 1313-25	4
157	Epigenetic alterations in acute myeloid leukemias. 2015 , 282, 1786-800	29
156	Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms. 2015 , 12, 7374-88	15
155	Epigenetics and Epigenetic Therapy of Cancer. 2015 , 72-79	
154	Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. 2015 , 26, 1069-77	16
153	The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. 2016 , 16, 20-8	17

152	Identification of potent histone deacetylase 8 inhibitors using pharmacophore-based virtual screening, three-dimensional quantitative structure–activity relationship, and docking study. 2015 , 21	3
151	Editorial: Antitarget Therapies: New Frontiers in the Treatment of Cancer. 2016 , 16, 4-6	
150	. 2015 ,	2
149	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. 2015 , 19, 1187-202	11
148	Chemotherapy is getting smarter <i>Future Oncology</i> , 2015 , 11, 549-52	3.6 9
147	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids. 2015 , 23, 7597-606	21
146	A review on pharmacophoric designs of antiproliferative agents. 2015 , 24, 903-920	36
145	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors. 2015 , 6, 239-43	50
144	Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update. 2015 , 10, 292-302	17
143	Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. 2015 , 7, 641-52	38
142	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents. 2015 , 23, 3457-71	21
141	Emerging approaches for histone deacetylase inhibitor drug discovery. 2015 , 10, 599-613	47
140	Interplay between histone acetylation/deacetylation and poly(ADP-ribosyl)ation in the development of ischemic tolerance in vitro. 2015 , 92, 125-34	15
139	Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. 2015 , 17, 26	50
138	RNA polymerase II pausing can be retained or acquired during activation of genes involved in the epithelial to mesenchymal transition. 2015 , 43, 3938-49	20
137	First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. 2015 , 33, 1048-57	15
136	Epigenetic-based therapy: From single- to multi-target approaches. 2015 , 69, 121-31	32
135	Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. 2015 , 33, 1280-91	1

134	Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. 2015 , 74, 257-64	33
133	Epigenetic drugs for cancer therapy. 2015 , 397-423	0
132	Novel β -Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway. 2015 , 58, 9214-27	55
131	Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia. 2015 , 168, 371-83	10
130	Targeting Histone Deacetylases in Diseases: Where Are We?. 2015 , 23, 99-126	89
129	Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. 2016 , 9, 6843-6855	22
128	Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells. 2016 , 9, 107	26
127	Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer. 2016 , 21,	42
126	Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia. 2016 , 172, 655-66	21
125	Epigenetic polypharmacology: from combination therapy to multitargeted drugs. 2016 , 8, 105	96
124	Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells. 2016 , 14, 3509-16	5
123	Sensitization strategies in lung cancer. 2016 , 12, 3669-3673	2
122	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells. 2016 , 36, 1875-85	22
121	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. 2016 , 8, 705-19	48
120	A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. 2016 , 27, 947-52	23
119	HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. 2016 , 25, 3887-3907	51
118	A combined pharmacophore modeling, 3D QSAR, virtual screening, molecular docking, and ADME studies to identify potential HDAC8 inhibitors. 2016 , 25, 2434-2450	4
117	PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment. 2016 , 44, 902-7	23

116	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. 2016 , 6, 986-1005	52
115	Nanocarrier-Based Anticancer Therapies with the Focus on Strategies for Targeting the Tumor Microenvironment. 2016 , 67-122	
114	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. 2016 , 29, 311-323	146
113	Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC. 2016 , 109, 1-12	42
112	Opportunities and challenges provided by crosstalk between signalling pathways in cancer. 2016 , 35, 1073-9	33
111	Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. 2017 , 77, 227-233	36
110	Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. 2017 , 17, 156	24
109	Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition. 2017 , 36, 4859-4874	13
108	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. 2017 , 58, 1880-1886	9
107	Plant-derived flavone Apigenin: The small-molecule with promising activity against therapeutically resistant prostate cancer. 2017 , 85, 47-56	36
106	Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC). 2017 , 18, 492-504	27
105	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. 2017 , 99, 153-164	52
104	CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response. 2017 , 102, 736-745	11
103	DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies. 2017 , 129, 1-13	66
102	Epigenomics, Pharmacoeigenomics, and Personalized Medicine in Cervical Cancer. 2017 , 20, 100-115	19
101	3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. 2017 , 20, 629-640	14
100	Death by HDAC Inhibition in Synovial Sarcoma Cells. 2017 , 16, 2656-2667	21
99	Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model. 2017 , 9, 988-999	11

98	Role of epigenome in tumorigenesis and drug resistance. 2017 , 109, 663-668	14
97	Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. 2017 , 9, 59	93
96	Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC). 2017 , 12, e0186208	35
95	Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer. 2018 , 275, 117-128	45
94	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. 2018 ,	11
93	Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs. 2018 , 26, 448-457	19
92	Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells. 2018 , 41, 201-212	27
91	Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. 2018 , 81, 483-495	10
90	CR2Cancer: a database for chromatin regulators in human cancer. 2018 , 46, D918-D924	14
89	AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. 2018 , 36, 1-9	12
88	Development of transplant immunosuppressive agents - considerations in the use of animal models. 2018 , 13, 1041-1053	6
87	Overview on Anticancer Drug Design and Development. 2018 , 25, 1704-1719	29
86	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. 2018 , 7, e1466018	32
85	Tricaproin Isolated From Inhibits the Growth of Human Colorectal Carcinoma Cell Lines by Targeting Class-1 Histone Deacetylases. 2018 , 9, 127	8
84	Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line. 2018 , 187, 126-143	4
83	Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents. 2018 , 19, 333-340	7
82	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. 2018 , 8, 92	356
81	The effects of nitidine chloride and camptothecin on the growth of Babesia and Theileria parasites. 2018 , 9, 1192-1201	19

80	SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis. 2018 , 6, 1	13
79	Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells. 2018 , 23,	29
78	Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering. 2019 , 11,	14
77	Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. 2019 , 10, 4192	27
76	A view on multi-action Pt(IV) antitumor prodrugs. 2019 , 492, 32-47	43
75	Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways. 2019 , 7, e613	8
74	Chemosensitizer effect of cisplatin-treated bladder cancer cells by phenazine-5,10-dioxides. 2019 , 69, 9-15	5
73	, a Treasured Medicinal Mushroom, Induces Growth Arrest in Breast Cancer Cells, T47D Cells: New Mechanisms Emerge. 2019 , 20,	9
72	Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. 2019 , 60, 675-684	11
71	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. 2019 , 62, 3171-3183	67
70	Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies. 2019 , 102, 163-173	22
69	A framework for identifying dysregulated chromatin regulators as master regulators in human cancer. 2019 , 35, 1805-1812	
68	Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma. 2019 , 139, 430-438	11
67	Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity. 2020 , 10, 1294-1308	17
66	Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. 2020 , 25,	10
65	The application of histone deacetylases inhibitors in glioblastoma. 2020 , 39, 138	29
64	Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. 2020 , 12,	6
63	Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme. 2020 , 11, 2962-2977	8

62	Design, Synthesis, and Biological Evaluation of Dual c-Met/HDAC Inhibitors Bearing 2-Aminopyrimidine Scaffold. 2020 , 02, e143-e149	0
61	Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. 2020 , 21,	6
60	Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation. 2020 , 63, 5956-5971	8
59	Tricaproin isolated from <i>Simarouba glauca</i> inhibit colorectal cancer cell growth: A mechanistic approach in vitro and in vivo. 2020 , 33, 2193-2202	
58	Impact of epigenetic modifiers on the immune system. 2020 , 315-352	
57	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. 2020 , 63, 4256-4292	30
56	HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. 2020 , 11, 472-482	22
55	Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of β -phenyl tropolone, HPOB, and sodium valproate. 2020 , 162, 151-165	7
54	Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair. 2020 , 12, 4429-4439	4
53	Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia. 2020 , 12, 107-128	2
52	HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. 2020 , 12,	6
51	PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. 2021 , 45, 100696	6
50	Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects. 2021 , 16, 448-457	3
49	New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents. 2021 , 21, 597-610	2
48	Delivery systems for vorinostat in cancer treatment: An updated review. 2021 , 61, 102334	1
47	Identification of In Vivo Metabolites of a Potential Anti-tumor Drug Candidate AMAC, in Rat Plasma, Urine and Feces Samples Using UHPLC/QTOF /MS/MS. 2021 , 17, 484-494	
46	Pancreatic INI1-deficient undifferentiated rhabdoid carcinoma achieves complete clinical response on gemcitabine and nab-paclitaxel following immediate progression on FOLFIRINOX: a case report. 2021 , 12, 874-879	0
45	Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders. 2021 , 216, 113332	5

44	An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality. 2021 , 18,	1
43	Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. 2021 , 13,	3
42	In silico study of the synergistic anti-tumor effect of hybrid topoisomerase-HDAC inhibitors. 2021 ,	
41	Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT). 2021 , 11, 648023	0
40	MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapy. 2021 , 514, 1-11	6
39	Microtubule associated proteins as targets for anticancer drug development. 2021 , 116, 105320	7
38	Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. 2021 , 225, 113768	8
37	Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. 2013 , 8, e58849	19
36	The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sézary Syndrome Alone or with Doxorubicin. 2016 , 11, e0146115	9
35	Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. 2018 , 9, 28155-28164	3
34	Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo. 2015 , 6, 35991-6002	5
33	Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. 2015 , 6, 33623-35	58
32	Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. 2016 , 7, 402-17	17
31	Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. 2020 , 27, 2449-2493	43
30	Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy. 2020 , 27, 7264-7288	14
29	The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment. <i>Future Oncology</i> , 2020 , 16, 2457-2469	3.6 3
28	Cinnamaldehyde, Cinnamic Acid, and Cinnamyl Alcohol, the Bioactives of Exhibit HDAC8 Inhibitory Activity: An and Study. 2017 , 13, S645-S651	7
27	Histones: Controlling Tumor Signaling Circuitry. 2013 , 1, 1-12	15

26	Advances in the Design and Development of PROTAC-mediated HDAC degradation. 2021 ,	1
25	Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2. 2021 , 50, 116454	0
24	CHAPTER 5:Targeting Histone Acetylation. 2015 , 96-126	
23	THE STUDY OF ANTITUMOR ACTIVITY OF PHENYLBUTYRATE IN COMBINATION WITH 5-FLUOROURACIL ON MODEL OF EHRlich CARCINOMA. 2017 , 16, 70-75	
22	Paradigms in Cancer Drug Development: A Universe with Many Galaxies. 2020 , 17-44	
21	Design, Synthesis, and Biological Evaluation of Dual c-Met/HDAC Inhibitors Bearing 2-Aminopyrimidine Scaffold. 2020 , 02, e117-e117	
20	The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death. 2013 , 5, 170-83	17
19	Epidrug Modulated Expression of MiR--152 and MiR-148a Reverse Cisplatin Resistance in Ovarian Cancer Cells: An Experimental In-vitro Study. 2020 , 19, 509-519	2
18	Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma. 2021 , 2021, 7850688	1
17	Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.. 2021 , 11, 786120	1
16	Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine. 2021 ,	1
15	Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair.. 2022 , 14, 259-271	4
14	Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.. 2022 , 1877, 188676	2
13	Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.. 2022 , 14,	3
12	Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically.. 2022 ,	1
11	Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres.. 2022 , 11,	1
10	Evodiamine-A Privileged Structure with Broad-Ranging Biological Activities.. 2022 ,	0
9	Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.. 2021 , 13,	1

8 Data_Sheet_1.DOC. **2018**,

7 Table_1.DOC. **2018**,

6 Sex-divergent expression of cytochrome P450 and SIRTUIN 1-7 proteins in toxicity evaluation of a benzimidazole-derived epigenetic modulator in mice.. *Toxicology and Applied Pharmacology*, **2022**, 445, 116039 4.6

5 Molecular basis of epigenetic regulation in cancer diagnosis and treatment. 13,

4 Novel epigenetic therapeutic strategies and targets in cancer. **2022**, 1868, 166552 1

3 The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. **2023**, 15, 62 0

2 Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from Elemene scaffold. **2023**, 38, 0

1 The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy. **2023**, 15, 2222 0